Two University of Michigan faculty elected to prestigious National Academy of Medicine

Author | Jina Sawani

University of Michigan experts in anesthesiology and radiation oncology are among the new members of the National Academy of Medicine of the National Academies, one of the highest honors in the fields of health and medicine. The institute was formerly called the Institute of Medicine.

George Mashour, M.D., Ph.D., and Lori J. Pierce, M.D., were elected to the NAM in recognition of their major contributions to the advancement of the medical sciences, health care and public health.

With their election, the U-M now has 58 members of the NAM on its active and emeritus faculty.

George A. Mashour, M.D, Ph.D., was appointed associate dean for clinical and translational research and director of the Michigan Institute for Clinical & Health Research (MICHR) in October 2015. He also serves as executive director of translational research in the Office of Research. The Bert N. La Du Professor of Anesthesiology Research in the Medical School, he holds additional faculty appointments in the Department of Neurosurgery and the Neuroscience Graduate Program.

In his capacity as associate dean, Dr. Mashour guides the translational research efforts of the Medical School in close partnership with the senior associate dean for research and other departments to enhance the quality and quantity of externally sponsored research. As director of MICHR, he oversees a unit that enables and enhances clinical and translational research by educating, funding, connecting, and supporting research teams across the University of Michigan and beyond.

Dr. Mashour received his medical degree and doctorate in neuroscience from Georgetown University. He was a Fulbright Scholar in neuroscience at the Max Delbruck Center for Molecular Medicine in Berlin, Germany, from 1998-99. He completed his internship at Harvard Medical School, postdoctoral research fellowship at the University of Bonn, Germany, and residency training at Harvard Medical School and Massachusetts General Hospital. He was a fellow in neurosurgical anesthesiology at the U-M, and in 2007 was appointed assistant professor in the departments of Anesthesiology and Neurosurgery. He was promoted to tenured associate professor in 2013 and was named the Bert N. La Du Professor of Anesthesiology Research in 2014.

He is an internationally recognized expert on the topics of consciousness, anesthetic mechanisms, and sleep. His investigations include a range of approaches, from computational modeling to animal studies to clinical trials. He has been well funded throughout the years and currently serves as the principal investigator of two R01 grants from the National Institutes of Health (NIH), and as lead principal investigator for a multi-centered James S. McDonnell Foundation grant.

Lori J. Pierce, M.D., FASTRO, FASCO, attended Duke University School of Medicine and completed a Radiation Oncology residency and chief residency at the Hospital of the University of Pennsylvania. She then was appointed as a Senior Investigator at the National Cancer Institute, National Institutes of Health in Bethesda, MD. In 1992, Dr. Pierce joined the faculty of the University of Michigan. Since coming to Michigan, she has served as residency director and clinical director in the Department of Radiation Oncology. In August 2005, Dr. Pierce was appointed by the University of Michigan Board of Regents to be Vice Provost for Academic and Faculty Affairs.

Her research focuses on the use of radiotherapy in the multi-modality treatment of breast cancer, with emphasis on intensity modulated radiotherapy in node positive breast cancer, the use of radiosensitizing agents, and the outcomes of radiation in women with breast cancer who carry a BRCA1/2 breast cancer susceptibility gene. She is also Director of the Michigan Radiation Oncology Quality Consortium (MROQC), a quality consortium of radiation oncology practices across the state of Michigan that seeks to establish best practices in the treatment of breast and lung cancers. This initiative is funded by Blue Cross Blue Shield of Michigan and Blue Care Network.

Dr. Pierce also co-founded PFS in order to help develop a diagnostic tool which will inform decision-making in the treatment to the breast in early stage breast cancer. While breast-conserving surgery and radiotherapy is a very effective treatment for most women with early stage disease, randomized clinical trials have shown that many women will not experience in-breast tumor recurrences following surgery only and a minority will recur even in the presence of radiotherapy. The difficulty is in identifying up front in-breast tumor recurrence risk. Development of gene profiles to aid in decision-making regarding the need for radiotherapy could minimize over-treatment and identify those tumors for which intensification of treatment is needed.

For more on the National Academy of Medicine, formerly the Institute of Medicine: http://nam.edu/

For a list of living NAM members on the U-M faculty (including emeritus): http://umhealth.me/NAM_UM

Media Contact Public Relations

Department of Communication at Michigan Medicine

[email protected]

734-764-2220

Featured News & Stories Moving illustration of family at the dinner table eating healthy diet
Health Lab
Playing short order cook, forcing clean plates may sabotage healthy eating habits in kids
While most parents of preschool and elementary aged children strive to give their children a balanced, nutritional diet, some of their strategies to promote healthy eating may backfire.
Pill capsule pushing through a paper with amoxicillin printed on it.
Health Lab
Rise seen in use of antibiotics for conditions they can’t treat – including COVID-19
Overuse of antibiotics can lead bacteria to evolve antimicrobial resistance, but Americans are still receiving the drugs for many conditions that they can’t treat.
Health Lab Podcast in brackets with a background with a dark blue translucent layers over cells
Health Lab Podcast
Study Shows Medical Marijuana Use Decreased in States with Legalized Recreational Use
The number of patients using cannabis for medical purposes has increased more than 600 percent since 2016.
Illustration of a microscope
Health Lab
Helpful enzymes vanish in many patients with antiphospholipid syndrome
Researchers recently revealed a new mechanism behind antiphospholipid syndrome that the investigators hope will eventually allow treatments to be targeted closer to the source of the problem.
marijuana leaf drawing blue lab note yellow badge upper left corner
Health Lab
Data shows medical marijuana use decreased in states where recreational use became legal 
Data on medical cannabis use found that enrollment in medical cannabis programs increased overall between 2016 and 2022, but enrollment in states where nonmedical use of cannabis became legal saw a decrease in enrollment
Illustration of hand holding list, with pill bottle in opposite and and small pic of doctor talking to patient
Health Lab
New urine-based test detects high grade prostate cancer, helping men avoid unnecessary biopsies
A new urine-based test addresses a major problem in prostate cancer: how to separate the slow growing form of the disease unlikely to cause harm from more aggressive cancer that needs immediate treatment.